Net revenues from sales declined 2% to RON203 million.
Operating costs dropped 2%, to RON199.7 million, the company said in a statement to the Bucharest Stock Exchange Thursday.
Ropharma estimates a 25% growth in profit this year to RON9 million, and a 5% growth in sales, to RON430 million.
In 2013, the company’s sales rose slightly to RON411.2 million and its profit increased nearly 3% to RON7.2 million.
Ropharma has two production units, in Targu Mures and Chisinau, where it makes nutritional supplements and medicines. The distribution company has five warehouses and 1,200 client pharmacies, besides its own drugstore network of 127 units.
Businessman Mihai Miron indirectly owns 31.65% of Ropharma. He controls 14.12% via Rimia Investments and 17.53% via ADD Pharmaceuticals, both registered in Cyprus. U.S.-registered Arrow Pharmaceuticals owns 31.29% in Ropharma. Other shareholders include private pension funds AZT Viitorul Tau – Allianz, with 5.87%, and private pension fund ING with 4.99%.